Table 1. Demographic characteristics of the study population according to the anti-AT1R results.

	anti-AT1R (+) (N = 5)	anti-AT1R (-) (N = 48)
Patient characteristics
Men, N (%)	3 (60 .0)	20 (41.7)
Recipients age (years, mean ± SD)	37.2 ± 10.9	45.0 ± 9.7
Retransplantation, N (%)	0 (0.0)	9 (18.8)
Cause of renal failure (N, %)
Chronic glomerulonephritis	1 (20.0)	25 (52.1)
Diabetic nephropathy	1 (20.0)	8 (16.7)
Hypertensive nephropathy	0 (0.0)	5 (10.4)
Polycystic kidney diseases	0 (0.0)	1 (2.1)
Others	3 (60.0)	9 (18.8)
Pre-transplant characteristics
Crossmatches (+), N (%)	2 (40.0)	6 (12.5)
N of HLA mismatches (mean ± SD)	3.6 ± 2.2	3.9 ± 1.3
Desensitization, N (%)	2 (40.0)	12 (25.0)
Donor characteristics
Donor age (years, mean ± SD)	3.62 ± 11.0	41 ± 14
Deceased donor, N (%)	0 (0.0)	17 (35.4)
Men, N (%)	4 (80.0)	29 (60.4)
At the time of biopsy (N, %)
anti-HLA Abs	4 (80.0)	36 (75.0)
anti-HLA class-I Abs	4 (80.0)	23 (47.9)
anti-HLA class-II Abs	2 (40.0)	31 (64.6)
DSA	4 (80.0)	22 (45.8)
DSA-HLA class-I*	4 (80.0)	6 (12.5)
MFI (mean ± SD)	2,259 ± 1,572	3,748 ± 4,291
DSA-HLA class-II	1 (20.0)	18 (37.5)
MFI (mean ± SD)	6756	7,708 ± 7,161
Time to rejection (months, mean ± SD)	45.9 ± 60.4	24.2 ± 38.7
graft failure	1 (20.0)	15 (31.3)
Histological findings (N, %)
AMR	3 (60.0)	19 (39.6)
TCMR	1 (20.0)	28 (58.3)
AMR and TCMR mixed rejection	1 (20.0)	1 (2.1)
C4d deposition	3 (60.0)	20 (41.7)
Severity of rejection (N, %)
TCMR Type IA/IB	1 (20.0)	24 (50.0)
TCMR Type IIA/IIB or AMR	4 (80.0)	24 (50.0)

^*Significant (P=0.003)

Abbreviations: Abs, antibodies; anti-AT1R, antibodies directed against AT1R; MFI, median fluorescence intensity; DSA, donor specific HLA antibodies; AMR, antibody-mediated rejection; TCMR, T-cell-mediated rejection.